Cor Vasa 2022, 64(3):291-299 | DOI: 10.33678/cor.2021.132
The power and wisdom of prevention. Cardiovascular risk, new challenge, and approach to PLWH
- a Department of Infectious and Tropical Diseases, Third Faculty of Medicine, Charles University and Na Bulovce Hospital, Prague
- b Department of Infectious and Tropical Diseases, First Faculty of Medicine, Charles University and Na Bulovce Hospital, Prague
- c Department of Biostatistics, National Institute of Public Health, Prague
- d Department of Infectious Diseases, Third Faculty of Medicine, Charles University and Na Bulovce Hospital, Prague and HIV/AIDS Center - Department of Infectious Diseases, Bulovka University Hospital, Prague
In recent years, quality of life is one of the important points of discussion among specialists working with people living with HIV (PLWH). With the introduction of highly effective antiretroviral therapy (1996), the expectation of life has dramatically increased and atherosclerotic diseases have become an important cause of morbidity and mortality in people infected with human immunodeficiency virus (HIV). Cardiovascular diseases are the third leading cause of mortality in HIV patients behind non-AIDS-related malignancies and non-AIDS-related infection. One of the many aspects in the treatment of PLWH concerns the prevention of cardiovascular diseases. The absolute risk of developing major cardiovascular disease events (CVD), for example, sudden cardiac death, cardiac arrest, and stroke in HIV-infected patients receiving antiretroviral therapy is still low. However, this risk is increased compared to the risk of uninfected people. This fact is substantially due to a higher prevalence of traditional cardiovascular risk factors that are mostly dependent on the host. Different types of antiretroviral treatment impact differently on metabolic effects and CVD. Prevention of cardiovascular disease in HIV-infected patients is an important goal for a better quality of life. Traditional risk factors should be detected and treated vigorously when possible, to avoid the development of major adverse cardiovascular events (MACE).
Keywords: Antiretroviral therapy, Atherosclerosis, Cardiovascular disease, Human immunodeficiency virus
Received: September 21, 2021; Revised: October 31, 2021; Accepted: November 16, 2021; Published: June 22, 2022 Show citation
References
- Samji H, Cescon A, Hogg RS, et al. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLoS One 2013;8:e81355.
Go to original source...
Go to PubMed...
- Brouillette J, Cyr S, Fiset C. Mechanisms of Arrhythmia and Sudden Cardiac Death in Patients With HIV Infection. Can J Cardiol 2019;35:310-319.
Go to original source...
Go to PubMed...
- Alonso A, Barnes AE, Guest JL, et al. HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a Large Healthcare Database. J Am Heart Assoc 2019;8:e012241.
Go to original source...
Go to PubMed...
- Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation 2019;140:e98-e124.
Go to original source...
Go to PubMed...
- Behrens G, Schmidt H, Meyer D, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958.
Go to original source...
Go to PubMed...
- Casale M, Mezzetti M, Tulino V, et al. Therapy Of Cardiac Arrhythmias In Children: An Emerging Role Of Electroanatomical Mapping Systems. Curr Vasc Pharmacol 2018;16:528-533.
Go to original source...
Go to PubMed...
- Rasmussen LD, Omland LH, Pedersen C, et al. Risk of myocardial infarction in parents of HIV-infected Individuals: a population-based Cohort Study. BMC Infect Dis 2010;10:169.
Go to original source...
Go to PubMed...
- Abdelazeem B, Gergis K, Baral N, et al. Sudden Cardiac Death and Sudden Cardiac Arrest in Patients with Human Immunodeficiency Virus: A Systematic Review. Cureus 2021;13:e13764.
Go to original source...
Go to PubMed...
- Monreal E, Gullón P, Pérez-Torre P, et al. Increased HIV infection in patients with stroke in Spain. A 16-year population-based study. Enferm Infecc Microbiol Clin (Engl Ed) 2020;38:219-225.
Go to original source...
Go to PubMed...
- Qureshi AI, Janssen RS, Karon JM, et al. Human Immunodeficiency Virus Infection and Stroke in Young Patients. Arch Neurol 1997;54:1150-1153.
Go to original source...
Go to PubMed...
- Hsue PY, Waters DD. Heart failure in persons living with HIV infection. Curr Opin HIV AIDS 2017;12:534-539.
Go to original source...
Go to PubMed...
- Paraskevas KI, Katsiki N, Tzovaras AA, et al. Peripheral Arterial Disease and HIV-Positive Patients. Angiology 2011;62:7-9.
Go to original source...
Go to PubMed...
- Hsue PY, Waters DD. Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor. Circulation 2018;138:1113-1115.
Go to original source...
Go to PubMed...
- Kelly SG, Plankey M, Post WS, et al. Associations between Tobacco, Alcohol, and Drug Use with Coronary Artery Plaque among HIV-Infected and Uninfected Men in the Multicenter AIDS Cohort Study. PLoS One 2016;11:e0147822.
Go to original source...
Go to PubMed...
- Naidu S, Ponnampalvanar S, Kamaruzzaman SB, et al. Prevalence of Metabolic Syndrome Among People Living with HIV in Developing Countries: A Systematic Review. AIDS Patient Care STDs 2017;31:1-13.
Go to original source...
Go to PubMed...
- Herrin M, Tate JP, Akgün KM, et al. Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals. J Acquir Immune Defic Syndr 2016;73:228-236.
Go to original source...
Go to PubMed...
- Maggi P, Di Biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis 2017;17:551.
Go to original source...
Go to PubMed...
- Rezaei S, Ahmadi S, Rahmati J, et al. Global prevalence of depression in HIV/AIDS: a systematic review and meta-analysis. BMJ Support Palliat Care 2019;9:404-412.
Go to original source...
Go to PubMed...
- Shah ASV, Stelzle D, Lee KK, et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV. Circulation 2018;138:1100-1112.
Go to original source...
Go to PubMed...
- Hsue PY. Mechanisms of Cardiovascular Disease in the Setting of HIV Infection. Can J Cardiol 2019;35:238-248.
Go to original source...
Go to PubMed...
- De Socio GV, Pasqualini M, Ricci E, et al. Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study. BMC Public Health 2020;20:734.
Go to original source...
Go to PubMed...
- Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHAGuideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2935-2959.
Go to original source...
Go to PubMed...
- Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-1482.
Go to original source...
Go to PubMed...
- Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten--year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
Go to original source...
Go to PubMed...
- Assmann G, Cullen P, Schulte H. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study. Circulation 2002;105:310-315.
Go to original source...
Go to PubMed...
- Serrano-Villar S, Estrada V, Gómez-Garre D, et al. Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms. Eur J Prev Cardiol 2014;21:739-748.
Go to original source...
Go to PubMed...
- Krikke M, Hoogeveen RC, Hoepelman AIM, et al. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models. HIV Medicine 2016;17:289-297.
Go to original source...
Go to PubMed...
- Anikpo I, Agovi AMA, Cvitanovich MJ, et al. The data- -collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV. HIV Med 2021;22:936-943.
Go to original source...
Go to PubMed...
- Schulz CA, Mavarani L, Reinsch N, et al. Prediction of future cardiovascular events by Framingham, SCORE and asCVD risk scores is less accurate in HIV-positive individuals from the HIV- -HEART Study compared with the general population. HIV Med 2021;22:732-741.
Go to original source...
Go to PubMed...
- Thompson-Paul AM, Lichtenstein KA, Armon C, et al. Cardiovascular Disease Risk Prediction in the HIV Outpatient Study. Clin Infect Dis 2016;63:1508-1516.
Go to original source...
Go to PubMed...
- Friis-Møller N, Ryom L, Smith C, et al. An updated prediction model of the global risk of cardiovascular disease in HIV- -positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol 2016;23:214-223.
Go to original source...
Go to PubMed...
- Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
Go to original source...
Go to PubMed...
- Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection. J Infect Dis 2010;201:1788-1795.
Go to original source...
Go to PubMed...
- Grunfeld C, Saag M, Cofrancesco JJ, et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 2010;24:1717-1726.
Go to original source...
Go to PubMed...
- Casale M, Quattrocchi S, Bitto R, et al. Cardiac implantable devices and takotsubo syndrome. A rare but potential eventuality. Cor Vasa 2018;60:e500-e502.
Go to original source...
- Casale M, Correale M, Laterra G, et al. Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study. Clin Drug Investig 2021;41:169-176.
Go to original source...
Go to PubMed...
- Casale M, Mezzetti M, De Fazio MG, et al. Usefulness of Sacubitril/Valsartan in reduction of atrial fibrillation burden in a patient with ICD delivering inappropriate therapies. A new possibility? Cor Vasa 2020;62:336-339.
Go to original source...
- Post WS, Budoff M, Kingsley L, et al. Associations Between HIV Infection and Subclinical Coronary Atherosclerosis. Ann Intern Med 2014;160:458-467.
Go to original source...
Go to PubMed...
- Haissman JM, Haugaard AK, Knudsen A, et al. Marker of Endothelial Dysfunction Asymmetric Dimethylarginine Is Elevated in HIV Infection but Not Associated With Subclinical Atherosclerosis. J Acquir Immune Defic Syndr 2016;73:507-513.
Go to original source...
Go to PubMed...
- Vos AG, Idris NS, Barth RE, et al. Pro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV Infection. A Systematic Review. PLoS One 2016;11:e0147484.
Go to original source...
Go to PubMed...
- Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
Go to original source...
Go to PubMed...
- Pisaturo M, Onorato L, Russo A, et al. Risk of failure in dual therapy versus triple therapy in naïve HIV patients: a systematic review and meta-analysis. Clin Microbiol Infect 2021;27:28-35.
Go to original source...
Go to PubMed...
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-1426.
- Baker JV, Sharma S, Achhra AC, et al. Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. J Am Heart Assoc 2017;6:e004987.
Go to original source...
Go to PubMed...
- Kuller LH, Tracy R, Belloso W, et al. Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. PLoS Med 2008;5:e203.
Go to original source...
Go to PubMed...
- Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17.
Go to original source...
Go to PubMed...
- The RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS 2021;35:869-882.
Go to original source...
Go to PubMed...
- O'Halloran JA, Sahrmann J, Butler AM, et al. Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV. J Acquir Immune Defic Syndr 2020;84:396-399.
Go to original source...
Go to PubMed...
- Blüher M, Kahn BB, Kahn CR. Extended Longevity in Mice Lacking the Insulin Receptor in Adipose Tissue. Science 2003;299:572-574.
Go to original source...
Go to PubMed...
- Willig AL, Overton ET. Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence. Curr HIV/AIDS Rep 2016;13:289-296.
Go to original source...
Go to PubMed...
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.